Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mark Cuban’s Generics Company Launches Online Pharmacy

Imatinib, Mesalamine And Colchicine Highlighted For ‘Striking Savings’

Executive Summary

Mark Cuban’s generics venture has launched its online pharmacy in the US, highlighting in particular three products – imatinib, mesalamine and colchicine – that it says “epitomize the pharmacy’s striking savings.”

You may also be interested in...



‘Disruptor’ Mark Cuban Takes Aim At US Industry Barriers

During a lively discussion at the AAM’s Access! conference in Orlando, billionaire entrepreneur Mark Cuban set out how he plans to use his Cost Plus Drugs company to disrupt the generics sector while also lifting its reputation by increasing trust and transparency among patients.

Mark Cuban’s US Pharma Ventures: Ally Or Gadfly In The Mix For Indian Firms?

Mark Cuban’s newly launched online pharmacy and pharmacy benefit manager operation in the US has sparked interest in India. Can the billionaire entrepreneur’s venture punch above its weight and should Indian firms be watchful?

Mark Cuban’s US Pharma Ventures: Ally Or Gadfly In The Mix For Indian Firms?

Mark Cuban’s newly launched online pharmacy and pharmacy benefit manager operation in the US spark interest in India. Can the billionaire entrepreneur’s venture punch above its weight and should Indian firms be watchful?

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel